Dholaria, Bhagirathbhai Labopin, Myriam Sanz, Jaime Ruggeri, Annalisa Cornelissen, Jan Labussière-Wallet, Hélène Blaise, Didier Forcade, Edouard Chevallier, Patrice Grassi, Anna
...
Published in
Journal of Hematology & Oncology
BackgroundAllogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) and cord blood transplantation (CBT) are valid alternatives for patients without a fully human leukocyte antigen (HLA)-matched donor. Here, we compared the allo-HCT outcomes of CBT versus single-allele-mismatched MMUD allo-HCT with post-tran...
Nagler, Arnon Labopin, Myriam Houhou, Mohamed Aljurf, Mahmoud Mousavi, Ashrafsadat Hamladji, Rose-Marie Al Zahrani, Mohsen Bondarenko, Sergey Arat, Mutlu Angelucci, Emanuele
...
Published in
Journal of Hematology & Oncology
BackgroundNon-T-cell depleted haploidentical hematopoietic stem cell transplantation (HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with improving patient outcomes. We have recently reported that outcomes of adult patients (pts) with ALL in complete remission (CR) receiving HaploSCT are comparable to unrelated donor tra...
Marquant, Kevin Quinquenel, Anne Arndt, Carl Denoyer, Alexandre
Published in
Journal of Hematology & Oncology
Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantamab mafodotin (belamaf), including ocular surface inflammation, severe dry eye, and a specific toxicity ...
Yu, Zhaojin Liu, Wensi He, Ying Sun, Mingli Yu, Jiankun Jiao, Xue Han, Qiang Tang, Haichao Zhang, Bing Xian, Yunkai
...
Published in
Journal of Hematology & Oncology
Hu, Jiahao Cao, Jiasheng Topatana, Win Juengpanich, Sarun Li, Shijie Zhang, Bin Shen, Jiliang Cai, Liuxin Cai, Xiujun Chen, Mingyu
...
Published in
Journal of Hematology & Oncology
TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. The p53-targeted therapy approach began with the identification of compounds capable of restoring/reactivating wild-type p53 functions or ...
Tahk, Siret Vick, Binje Hiller, Björn Schmitt, Saskia Marcinek, Anetta Perini, Enrico D. Leutbecher, Alexandra Augsberger, Christian Reischer, Anna Tast, Benjamin
...
Published in
Journal of Hematology & Oncology
Background Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting with myeloid-specific signal regulatory protein alpha (SIRPα). Activation of macrophages by blocking CD47 has been successful, but th...
Zhu, Shaoming Zhang, Tian Zheng, Lei Liu, Hongtao Song, Wenru Liu, Delong Li, Zihai Pan, Chong-xian
Published in
Journal of Hematology & Oncology
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience...
Gao, Ruitian Zhao, Shuai Aishanjiang, Kedeerya Cai, Hao Wei, Ting Zhang, Yichi Liu, Zhikun Zhou, Jie Han, Bing Wang, Jian
...
Published in
Journal of Hematology & Oncology
Background Liver cancer remains the leading cause of cancer death globally, and the treatment strategies are distinct for each type of malignant hepatic tumors. However, the differential diagnosis before surgery is challenging and subjective. This study aims to build an automatic diagnostic model for differentiating malignant hepatic tumors based o...
Shi, Zhaopeng Gan, Guifang Xu, Xiang Zhang, Jieying Yuan, Yuan Bi, Bo Gao, Xianfu Xu, Pengfei Zeng, Wenbin Li, Jixi
...
Published in
Journal of Hematology & Oncology
The 3-hydroxyanthranilic acid (3-HAA), a derivative of kynurenine, was reported to suppress tumor growth. However, the function of 3-HAA largely remains unclear. Here, we report that 3-hydroxyanthranilic acid (3-HAA) is lower in tumor cells, while adding exogenous 3-HAA induces apoptosis in hepatocellular carcinoma by binding YY1. This 3-HAA bindin...
Wang, Chunmeng Shi, Fengxia Liu, Yang Zhang, Yajing Dong, Liang Li, Xiang Tong, Chuan Wang, Yao Su, Liping Nie, Jing
...
Published in
Journal of Hematology & Oncology
